<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJPsych</journal-id><journal-title-group><journal-title>Open Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="epub">2161-7325</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojpsych.2014.43033</article-id><article-id pub-id-type="publisher-id">OJPsych-48094</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>BIOMEDICAL &amp; LIFE SCIENCES</subject></subj-group></article-categories><title-group><article-title>Rapid Tranquillisation: An AGREEable Ground?</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pallavi</surname><given-names>Nadkarni</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mahesh</surname><given-names>Jayaram</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Shailesh</surname><given-names>Nadkarni</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ranga</surname><given-names>Rattehalli</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Clive</surname><given-names>Adams</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Psychiatry, Queen’s University, Kingston, Canada</addr-line></aff><aff id="aff3"><addr-line>National Research Corporation Canada, Markham, Canada</addr-line></aff><aff id="aff5"><addr-line>The University of Nottingham, Jubliee Campus, Nottingham, UK</addr-line></aff><aff id="aff4"><addr-line>Newsam Centre, Seacroft Hospital, Leeds, UK</addr-line></aff><aff id="aff2"><addr-line>Department of Psychiatry, The University of Melbourne, Level 1 North, Main Block, Royal Melbourne Hospital VIC 3050 Australia</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>nadkarnp@kgh.kari.net(PN)</email>;<email>Mahesh.Jayaram@unimelb.edu.au(MJ)</email>;<email>snadkarni@nationalresearch.ca(SN)</email>;<email>rdrattehalli@hotmail.com(RR)</email>;<email>clive.adams@nottingham.ac.uk(CA)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>06</month><year>2014</year></pub-date><volume>04</volume><issue>03</issue><fpage>269</fpage><lpage>274</lpage><history><date date-type="received"><day>1</day>	<month>May</month>	<year>2014</year></date><date date-type="rev-recd"><day>30</day>	<month>May</month>	<year>2014</year>	</date><date date-type="accepted"><day>26</day>	<month>June</month>	<year>2014</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
	Objective:
Evidence base for rapid tranquillisation is an under researched area. Guidelines
on rapid tranquilisation from English speaking countries were appraised using
AGREE (Appraisal of Guidelines Research and Evaluation) and differences in
their recommendations were analysed. Methods: Four independent psychiatrists
appraised the guidelines using the AGREE tool. AGREE is a validated instrument
used to assess the quality of guideline and recommendations using six domains
of which each domain captures a specific aspect of the guideline development.
The content was analysed manually. Results: Seven guidelines from five English
speaking countries met the inclusion criteria. All the guidelines scored well
on the domain of “scope and purpose”. NICE guidelines from the UK consistently
scored well on all domains with the maximum possible score of 100 on the “applicability”
domain. APA from the USA did well on the domain of “editorial independence”.
AGREE could only examine the guideline development process and not the content.
The guidelines differed in their recommendations of choice of drug for rapid
tranquillisation. Discussion: All guidelines scored reasonably well on AGREE.
National Institute of Clinical Excellence (NICE) has used robust strategies in
developing the guidelines. Guidelines failed to achieve consensus in
recommendations despite using a common pool of evidence. Haloperidol-promethazine
combination is not recommended by any with the exception of NICE. This suggests
data is selectively interpreted depending on locally prevalent customs.
</p></abstract><kwd-group><kwd>Tranquillisation</kwd><kwd> Guidelines</kwd><kwd> Anti-Psychotics</kwd><kwd> Psychiatric Emergencies</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Violent or aggressive behaviour is a psychiatric emergency that necessitates swift mobilisation of staff and resources. Commonly it is secondary to psychotic symptoms, physical illness (e.g. delirium) and substance abuse [<xref ref-type="bibr" rid="scirp.48094-ref1">1</xref>] . Violent behaviour in an emergency room setting elicits varied responses and inexperienced staff may be required to handle such situations. This can have an impact on care of other patients with acute medical problems. On psychiatric wards, violent behaviour is likely to provoke aggression amongst other inpatients thereby stretch- ing staff resources. Effective management of these volatile situations can reduce risks to the patient, other service users, staff and family members who are often victims of aggression [<xref ref-type="bibr" rid="scirp.48094-ref2">2</xref>] .</p><p>Rapid tranquillisation is the use of medication to manage agitated or aggressive behaviour [<xref ref-type="bibr" rid="scirp.48094-ref3">3</xref>] and is used when other psychological and behavioural approaches have failed to calm the patient. A literature search of rapid tranquillisation revealed eight surveys of clinical practice and two surveys of clinician preferences (<xref ref-type="table" rid="table1">Table 1</xref>). There was failure of consensus on choice of medication for rapid tranquillisation—probably reflecting local cultural influences on prescription practices. All but one survey were from the western world. Appraisal of various guidelines around the world for schizophrenia suggests that recommendations are not uniform and quality of guideline may vary [<xref ref-type="bibr" rid="scirp.48094-ref4">4</xref>] . We have not come across any similar appraisal of guidelines on rapid tranquillisation and this is one important piece of the puzzle that we felt needs to be solved.</p><table-wrap id="table1"  position="float"><object-id pub-id-type="pii">Table 1</object-id><label>Table 1</label><caption><p>. Surveys on rapid tranquillisation</p></caption><table><thead><tr><th align="center" valign="middle" >Year</th><th align="center" valign="middle" >Authors</th><th align="center" valign="middle" >Methods</th><th align="center" valign="middle" >Participants</th><th align="center" valign="middle" >Location</th><th align="center" valign="middle" >Response</th><th align="center" valign="middle" >Duration</th><th align="center" valign="middle" >Results</th></tr></thead><tbody><tr><td align="center" valign="middle" >1992</td><td align="center" valign="middle" >Pilowsky et al.</td><td align="center" valign="middle" >Retrospective practice-based</td><td align="center" valign="middle" >Doctors and nurses</td><td align="center" valign="middle" >South  London, UK</td><td align="center" valign="middle" >95%</td><td align="center" valign="middle" >6 months</td><td align="center" valign="middle" >Mean doses of parenteral antipsychotics and  sedatives exceeded BNF* recommendations.</td></tr><tr><td align="center" valign="middle" >1994</td><td align="center" valign="middle" >Cunnane et al.</td><td align="center" valign="middle" >Retrospective vignette-based</td><td align="center" valign="middle" >General adult  consultants</td><td align="center" valign="middle" >Oxford, UK</td><td align="center" valign="middle" >68%</td><td align="center" valign="middle" >Not  mentioned</td><td align="center" valign="middle" >No clear consensus. Chlorpromazine  preferred over haloperidol. IM route favoured.</td></tr><tr><td align="center" valign="middle" >1996</td><td align="center" valign="middle" >Simpson et al.</td><td align="center" valign="middle" >Retrospective vignette-based</td><td align="center" valign="middle" >Consultants and registrars</td><td align="center" valign="middle" >Manchester, UK</td><td align="center" valign="middle" >67%</td><td align="center" valign="middle" >Not  mentioned</td><td align="center" valign="middle" >Haloperidol preferred to chlorpromazine.  BNF maximum doses felt to be inadequate to  control severe aggression.</td></tr><tr><td align="center" valign="middle" >1997</td><td align="center" valign="middle" >Mannion et al.</td><td align="center" valign="middle" >Retrospective practice-based</td><td align="center" valign="middle" >Psychiatry  trainees</td><td align="center" valign="middle" >Dublin,  Ireland</td><td align="center" valign="middle" >80%</td><td align="center" valign="middle" >6 months</td><td align="center" valign="middle" >High dose antipsychotics and IM routes  preferred. Zuclopenthixol acetate used in  nearly half the incidents.</td></tr><tr><td align="center" valign="middle" >1998</td><td align="center" valign="middle" >Hyde  et al.</td><td align="center" valign="middle" >Retrospective practice-based</td><td align="center" valign="middle" >Nurse-based  computerised  database</td><td align="center" valign="middle" >Manchester, UK</td><td align="center" valign="middle" >100%</td><td align="center" valign="middle" >24 months</td><td align="center" valign="middle" >Zuclopenthixol or haloperidol + lorazepam  IM preferred. Higher doses used in disturbed  or resistant cases.</td></tr><tr><td align="center" valign="middle" >1999</td><td align="center" valign="middle" >Binder  et al.</td><td align="center" valign="middle" >Retrospective practice-based</td><td align="center" valign="middle" >Medical directors  of emergency  settings</td><td align="center" valign="middle" >USA-wide</td><td align="center" valign="middle" >100%</td><td align="center" valign="middle" >1 month</td><td align="center" valign="middle" >Haloperidol-lorazepam combination favoured.  IM route preferred.</td></tr><tr><td align="center" valign="middle" >1999</td><td align="center" valign="middle" >Moritz  et al.</td><td align="center" valign="middle" >Prospective  practice-based</td><td align="center" valign="middle" >100 consecutive patients in  emergency room</td><td align="center" valign="middle" >Rouen,  France</td><td align="center" valign="middle" >100%</td><td align="center" valign="middle" >9 months</td><td align="center" valign="middle" >Intramuscular loxapine was the preferred drug  of choice.</td></tr><tr><td align="center" valign="middle" >2002</td><td align="center" valign="middle" >Huf et al.</td><td align="center" valign="middle" >Retrospective practice-based</td><td align="center" valign="middle" >Practitioners in psychiatric  emergency room</td><td align="center" valign="middle" >Rio de  Janeiro,  Brazil</td><td align="center" valign="middle" >100%</td><td align="center" valign="middle" >1 week</td><td align="center" valign="middle" >Haloperidol-promethazine combination  preferred by 83% of participants.</td></tr><tr><td align="center" valign="middle" >2003</td><td align="center" valign="middle" >Reid  et al.</td><td align="center" valign="middle" >Retrospective practice-based</td><td align="center" valign="middle" >Consultants</td><td align="center" valign="middle" >West  Scotland,  UK</td><td align="center" valign="middle" >84%</td><td align="center" valign="middle" >Not  mentioned</td><td align="center" valign="middle" >Droperidol perceived to be more effective  than haloperidol or chlorpromazine  Disapproval at its withdrawal.</td></tr><tr><td align="center" valign="middle" >2005</td><td align="center" valign="middle" >Pereira et al.</td><td align="center" valign="middle" >Retrospective practice-based</td><td align="center" valign="middle" >Consultants and trainees</td><td align="center" valign="middle" >UK-wide</td><td align="center" valign="middle" >22%</td><td align="center" valign="middle" >Not  mentioned</td><td align="center" valign="middle" >Lorazepam and haloperidol favoured with  most doses exceeding BNF limits.  Chlorpromazine, zuclopenthixol and  droperidol next in line.</td></tr></tbody></table></table-wrap><p>: Surveys of clinicians’ preferred choices; <sup>*</sup>BNF: British National Formulary.</p></sec><sec id="s2"><title>2. The Instrument and Its Scope</title><p>The Appraisal of Guidelines Research and Evaluation (AGREE) is an instrument used to assess the methodological rigour and potential biases involved in guideline development. It also checks for the internal and external validity of the recommendations [<xref ref-type="bibr" rid="scirp.48094-ref5">5</xref>] . It can assess any new, existing or updated guideline. It consists of 23 key items organised in six domains each of which rates a separate dimension of guideline. Domain 1 is “Scope and Purpose” which captures the overall aim of the guideline and its target group. Domain 2 is “Stakeholder Involvement” which captures the extent to which appropriate stakeholders were involved in developing the guideline and also represents the views of its intended users. Domain 3 is “Rigour of Development” which looks at the process of gathering and summarizing the evidence used and the methods used to develop its recommendations. Domain 4 is “Clarity of Presentation” capturing the language, structure and format of the guideline. Domain 5 is “Applicability” looking at the potential barriers and facilitators to implementation, strategies to improve uptake and resources needed to implement the guideline. Domain 6 is “Editorial Independence” which captures biases caused by any other competing interests.</p><p>Four independent raters rate the guidelines on these domains using a four point scale. The scores on the six domains are independent and cannot be aggregated. These scores help to compare the different guidelines and to decide whether or not to recommend a particular guideline over others. However it is not possible to set thresholds for the domain scores to demarcate a good guideline from a bad one.</p></sec><sec id="s3"><title>3. Method</title><p>Guidelines on rapid tranquillisation from all English speaking countries were appraised using AGREE, with special emphasis on the NICE guidelines [<xref ref-type="bibr" rid="scirp.48094-ref6">6</xref>] . An English-speaking country was defined as a country with English as one of the official languages and with more than 50% residents speaking English. The 50% mark was arbitrarily chosen as a cut off figure. This was because countries where the majority of the population spoke a language other than English as first language were likely to have guidelines in local languages. This meant that there would be innumerable guidelines to assess, which would have been difficult to achieve given the language barrier.</p><p>Major databases were searched through the electronic database OVID. The databases included EMBASE (1980 to October week 3 2008), CINAHL (1982 to October week 3 2008), MEDLINE (1950 to October week 3 2008) and PsycINFO (1806 to October week 3 2008).The search terms used were “rapid tranquillisation” “tranquillisation” “behavioural emergencies”, “aggression”, “psychiatry emergencies”, ”guidelines in psychiatry” and “expert consensus guidelines”. After dropping the duplicates and hand searching the abstracts seven guidelines in English language were obtained from five countries: UK, USA, Canada, Australia and New Zealand which met our inclusion criteria. The eighth guideline from Singapore was excluded as it did not meet the criterion of an English-speaking country.</p><p>Four raters used the AGREE tool to objectively assess potential biases of guidelines. The assessors were trainee psychiatrists at different levels of their training. Two of them were senior house officers: one in his first year of training and the second in his second year of training. A specialist registrar (one of the authors) and a staff grade psychiatrist both in their fourth year of training formed the team of assessors. The raters had received prior instructions regarding the scoring process. The guidelines were scored on six domains mentioned above. The scores were then standardised according to validated recommendations which could range from 0 to 100%. The content of the guidelines was analysed separately as it was not rated by the AGREE tool.</p></sec><sec id="s4"><title>4. Results</title><p>Seven guidelines identified as above were compared for their pharmacological recommendations (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>Their methodological quality was evaluated using AGREE (<xref ref-type="table" rid="table3">Table 3</xref>). The scores from the four raters on the AGREE instrument ranged from a minimum of 33 on the domain of applicability for APA guidelines to the maximum of 100 on the applicability domain of NICE guidelines and editorial independence domain of the APA guidance. All guidelines scored well on the domain of scope and purpose. The NICE guidelines consistently scored well on all domains with the exception of editorial independence on which it performed mode rately with a score of 63.</p><table-wrap id="table2"  position="float"><object-id pub-id-type="pii">Table 2</object-id><label>Table 2</label><caption><p>. Guideline recommendations for rapid tranquillisation</p></caption><table><thead><tr><th align="center" valign="middle" >Date</th><th align="center" valign="middle" >Source</th><th align="center" valign="middle" >Guideline</th><th align="center" valign="middle"  colspan="2"  >Drugs recommended</th><th align="center" valign="middle" >Route of admin</th><th align="center" valign="middle" >Comments</th></tr></thead><tbody><tr><td align="center" valign="middle"  rowspan="2"  >2004</td><td align="center" valign="middle"  rowspan="2"  >USA</td><td align="center" valign="middle"  rowspan="2"  >American  Psychiatric  Association (APA)</td><td align="center" valign="middle"  colspan="2"  >Dissolvable olanzapine/risperidone OR Concentrate formulation of  risperidone/haloperidol</td><td align="center" valign="middle" >PO</td><td align="center" valign="middle"  rowspan="2"  >Droperidol: in selected clinical situations of  extreme emergency or in highly agitated patients.</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Haloperidol/ziprasidone/ olanzapine +/− lorazepam</td><td align="center" valign="middle" >IM</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >2005</td><td align="center" valign="middle"  rowspan="2"  >Canada</td><td align="center" valign="middle"  rowspan="2"  >Canadian  Psychiatric  Association (CPA)</td><td align="center" valign="middle"  colspan="2"  >Dissolvable SGAs</td><td align="center" valign="middle" >PO</td><td align="center" valign="middle"  rowspan="2"  >Zuclopenthixol acetate: recommended to avoid  repeated injections, except in drug na&#239;ve patients.</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Haloperidol 5 mg + lorazepam 2 mg OR olanzapine (2.5 - 10 mg)</td><td align="center" valign="middle" >IM</td></tr><tr><td align="center" valign="middle"  rowspan="4"  >2005</td><td align="center" valign="middle"  rowspan="4"  >USA</td><td align="center" valign="middle"  rowspan="4"  >Expert  Consensus Guidelines  (ECG)</td><td align="center" valign="middle" >Personality  disorder/ Intoxication/  No data </td><td align="center" valign="middle" >Benzodiazepines</td><td align="center" valign="middle" >PO</td><td align="center" valign="middle"  rowspan="4"  >Medication and patient characteristics govern the  choice of psychotropic used</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Schizophrenia/ Mania</td><td align="center" valign="middle" >Olanzapine/risperidone +/−BNZ/ haloperidol +  BNZ/valproex + antipsychotic</td><td align="center" valign="middle" >PO</td></tr><tr><td align="center" valign="middle" >Ziprasidone/quetiapine</td><td align="center" valign="middle" >PO</td></tr><tr><td align="center" valign="middle" >Olanzapine/ziprasidone +/− BNZ/haloperidol + BNZ</td><td align="center" valign="middle" >IM</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >2005</td><td align="center" valign="middle"  rowspan="2"  >UK</td><td align="center" valign="middle"  rowspan="2"  >National  Institute for  Clinical  Excellence  Guidelines  (NICE)</td><td align="center" valign="middle"  colspan="2"  >Haloperidol/lorazepam/  olanzapine/risperidone</td><td align="center" valign="middle" >PO</td><td align="center" valign="middle"  rowspan="2"  >Olanzapine/risperidone: avoid in dementia.  IV benzodiazepine/haloperidol: exceptional cases Oral or IM lorazepam alone: non-psychotic  behavioural disturbance IM (haloperiodol + promethazine) /IM  midazolam: very exceptional cases. Zuclopenthixol acetate: recommended in few,  other than drug na&#239;ve patients. Chlorpromazine:  not recommended at all.</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Haloperidol + lorazepam OR Olanzapine</td><td align="center" valign="middle" >IM</td></tr><tr><td align="center" valign="middle" >2003</td><td align="center" valign="middle" >USA</td><td align="center" valign="middle" >Patient  Outcomes  Research  Team  (PORT)</td><td align="center" valign="middle"  colspan="2"  >Antipsychotic + benzodiazepine</td><td align="center" valign="middle" >Not  specified</td><td align="center" valign="middle" >No details explained.</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >2004</td><td align="center" valign="middle"  rowspan="3"  >Australia &amp; New  Zealand</td><td align="center" valign="middle"  rowspan="3"  >Royal  Australian &amp;  New  Zealand College of  Psychiatrists  (RANZP)</td><td align="center" valign="middle"  colspan="2"  >Lorazepam (1 - 2 mg)/diazepam (5 - 10 mg) </td><td align="center" valign="middle" >PO</td><td align="center" valign="middle"  rowspan="3"  >Typical antipsychotics: recommended as a last  resort owing to risk of EPS. Haloperidol: least effective strategy. Alternative options: chlorpromazine (50 - 100 mg  PO)/clonazepam (0.5 - 2 mg IM)/olanzapine(IM).  Droperidol (IM): in nonresponsive cases.  Zuclopenthixol acetate: recommended to avoid  frequent injections even in drug na&#239;ve patients. IV  midazolam may be used for rapid onset of action.</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Olanzapine wafers (5 - 10 mg)/ quetiapine (50 - 100 mg)</td><td align="center" valign="middle" >PO</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Midazolam 5 mg</td><td align="center" valign="middle" >IM</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >2003</td><td align="center" valign="middle"  rowspan="3"  >USA</td><td align="center" valign="middle"  rowspan="3"  >Texas  Implementation of Medication  Algorithms (TIMA)</td><td align="center" valign="middle"  colspan="2"  >Benzodiazepine/FGA</td><td align="center" valign="middle" >PO/IM</td><td align="center" valign="middle"  rowspan="3"  >Benzodiazepines (lorazepam 1 - 8 mg/day,  clonazepam 0.5 - 2 mg/day) &amp; FGAs: preferred  over SGAs irrespective of route. SGAs seem less effective for agitation/ excitement  of an acute exacerbation.</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Risperidone solution</td><td align="center" valign="middle" >PO</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Olanzapine/ziprasidone</td><td align="center" valign="middle" >IM</td></tr></tbody></table></table-wrap><p>FGA = first generation antipsychotic; SGA = second generation antipsychotic; BNZ = benzodiazepine. Colour code: Yellow = 1<sup>st</sup> choice, Green = 2<sup>nd</sup> choice, Red = 3<sup>rd</sup> choice.</p></sec><sec id="s5"><title>5. Discussion</title><p>Common themes in clinical practice can be identified. For instance, benzodiazepines are chosen when little background information about the patient is available. This is in keeping with the Expert Consensus Guidelines [<xref ref-type="bibr" rid="scirp.48094-ref7">7</xref>] . Benzodiazepines are administered in psychiatric emergencies more frequently than other agents especially when the diagnosis is unknown [<xref ref-type="bibr" rid="scirp.48094-ref8">8</xref>] . Haloperidol plus promethazine combination is prevalent in Brazil [<xref ref-type="bibr" rid="scirp.48094-ref9">9</xref>] and India [<xref ref-type="bibr" rid="scirp.48094-ref10">10</xref>] . Its use is supported by high quality evidence showing its consistent superiority over olanzapine, lorazepam and haloperidol [<xref ref-type="bibr" rid="scirp.48094-ref10">10</xref>] . However this combination does not find a place in most guidelines with the exception of NICE. Lack of uniformity in recommendations despite using a common evidence pool is indeed intriguing. This could be a result of having only small trials with methodological inadequacies in this area. The</p><table-wrap id="table3"  position="float"><object-id pub-id-type="pii">Table 3</object-id><label>Table 3</label><caption><p>. Methodological quality of guidelines</p></caption><table><thead><tr><th align="center" valign="middle"  rowspan="2"  >Guideline</th><th align="center" valign="middle"  colspan="6"  >Standardised AGREE Scores for each Domain (Percentage of maximum available score)</th></tr></thead><tbody><tr><td align="center" valign="middle" >Domain 1 Scope &amp; Purpose</td><td align="center" valign="middle" >Domain 2 Stakeholder involvement</td><td align="center" valign="middle" >Domain 3 Rigour of  development</td><td align="center" valign="middle" >Domain 4 Clarity &amp;  presentation</td><td align="center" valign="middle" >Domain 5 Applicability</td><td align="center" valign="middle" >Domain 6 Editorial  independence</td></tr><tr><td align="center" valign="middle" >APA</td><td align="center" valign="middle" >94</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >90</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" >CPA</td><td align="center" valign="middle" >94</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >93</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >96</td></tr><tr><td align="center" valign="middle" >ECG</td><td align="center" valign="middle" >94</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >79</td></tr><tr><td align="center" valign="middle" >NICE</td><td align="center" valign="middle" >97</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >63</td></tr><tr><td align="center" valign="middle" >PORT</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >85</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >58</td></tr><tr><td align="center" valign="middle" >RANZP</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >83</td></tr><tr><td align="center" valign="middle" >TIMA</td><td align="center" valign="middle" >92</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >46</td></tr></tbody></table></table-wrap><p>lack of good quality evidence necessitates those drawing up guidance to draw conclusions that are not founded on best possible evidence. For instance the only existing trial of zuclopenthixol acetate has a sample size of 40 patients [<xref ref-type="bibr" rid="scirp.48094-ref11">11</xref>] yet Australian and New Zealand guidelines [<xref ref-type="bibr" rid="scirp.48094-ref12">12</xref>] recommend it for rapid tranquillisation unlike the NICE and Canadian guidelines [<xref ref-type="bibr" rid="scirp.48094-ref13">13</xref>] . However even the NICE and Canadian guidelines have used equally thin evidence base for their recommendations. They differ on their inclusion of first and second generation anti psychotics thereby suggesting that guidelines are a combination of personal preferences and evidence base that is in turn influenced by selective interpretation of data.</p><p>Consensus on rapid tranquillisation guidelines is the need of the hour. Whether better quality clinical trials can help us reach an AGREEment remains to be seen.</p></sec><sec id="s6"><title>Declaration of Interest</title><p>None.</p></sec></body><back><ref-list><title>References</title><ref id="scirp.48094-ref1"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>ATAKAN</surname><given-names> Z.D. </given-names></name>,<etal>et al</etal>. (<year>1997</year>)<article-title>ABC OF MENTAL HEALTH. MENTAL HEALTH EMERGENCIES</article-title><source>. BMJ</source><volume> 314</volume>,<fpage> 1740</fpage>-<lpage>1742</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1136/BMJ.314.7096.1740</pub-id></mixed-citation></ref><ref id="scirp.48094-ref2"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>MACPHERSON</surname><given-names> R.</given-names></name>,<name name-style="western"><surname> DIX</surname><given-names> R. </given-names></name>,<name name-style="western"><surname> MORGAN</surname><given-names> S. </given-names></name>,<etal>et al</etal>. (<year>2005</year>)<article-title>A GROWING EVIDENCE BASE FOR MANAGEMENT GUIDELINES</article-title><source>. ADVANCES IN PSYCHIATRIC TREATMENT</source><volume> 11</volume>,<fpage> 404</fpage>-<lpage>415</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1192/APT.11.6.404</pub-id></mixed-citation></ref><ref id="scirp.48094-ref3"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>PEREIRA</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> PATON</surname><given-names> C.</given-names></name>,<name name-style="western"><surname> WALKERT</surname><given-names> L.</given-names></name>,<name name-style="western"><surname> ET AL. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2005</year>)<article-title>TREATMENT OF ACUTE BEHAVIOURAL DISTURBANCE: A UK NATIONAL SURVEY OF RAPID TRANQUILLISATION</article-title><source>. JOURNAL OF PSYCHIATRIC INTENSIVE CARE</source><volume> 1</volume>,<fpage> 84</fpage>-<lpage>88</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1017/S1742646406000148</pub-id></mixed-citation></ref><ref id="scirp.48094-ref4"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>GAEBEL</surname><given-names> W.</given-names></name>,<name name-style="western"><surname> WEINMANN</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> SARTORIUS</surname><given-names> N.</given-names></name>,<name name-style="western"><surname> RUTZ</surname><given-names> W. </given-names></name>,<name name-style="western"><surname> MCINTYRE</surname><given-names> J.S. </given-names></name>,<etal>et al</etal>. (<year>2005</year>)<article-title>SCHIZOPHRENIA PRACTICE GUIDELINES: INTERNATIONAL SURVEY AND COMPARISON</article-title><source>. THE BRITISH JOURNAL OF PSYCHIATRY</source><volume> 187</volume>,<fpage> 248</fpage>-<lpage>255</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1192/BJP.187.3.248</pub-id></mixed-citation></ref><ref id="scirp.48094-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">THE AGREE COLLABORATION. APPRAISAL OF GUIDELINES FOR RESEARCH AND EVALUATION (AGREE) INSTRUMENT (ACCESSED 21 MARCH 2008). HTTP://WWW.AGREECOLLABORATION.ORG</mixed-citation></ref><ref id="scirp.48094-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE: CLINICAL GUIDELINE 25. VIOLENCE: THE SHORT-TERM MANAGEMENT OF DISTURBED/VIOLENT BEHAVIOUR IN IN-PATIENT PSYCHIATRIC SETTINGS AND EMERGENCY DEPARTMENTS. LONDON: NICE 2005.</mixed-citation></ref><ref id="scirp.48094-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">EXPERT CONSENSUS PANEL FOR BEHAVIOURAL EMERGENCIES: EXPERT CONSENSUS GUIDELINE SERIES. TREATMENT OF BEHAVIOURAL EMERGENCIES. JOURNAL OF PSYCHIATRIC PRACTICE, 2005, 11, 5-108.</mixed-citation></ref><ref id="scirp.48094-ref8"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>MACPHERSON</surname><given-names> R.</given-names></name>,<name name-style="western"><surname> DIX</surname><given-names> R. </given-names></name>,<name name-style="western"><surname> MORGAN</surname><given-names> S. </given-names></name>,<etal>et al</etal>. (<year>2005</year>)<article-title>A GROWING EVIDENCE BASE FOR MANAGEMENT GUIDELINES</article-title><source>. ADVANCES IN PSYCHIATRIC TREATMENT</source><volume> 11</volume>,<fpage> 404</fpage>-<lpage>415</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1192/APT.11.6.404</pub-id></mixed-citation></ref><ref id="scirp.48094-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">HUF, G., COUTINHO, E., FAGUNDES JR., H., OLIVEIRA, E., LOPEZ, J., GEWANDSZAJDER, M., CARVALHO, A., KEUSEN, A. AND ADAMS, C. (2002) CURRENT PRACTICES IN MANAGING ACUTELY DISTURBED PATIENTS AT THREE HOSPITALS IN RIO DE JANEIRO-BRAZIL: A PREVALENCE STUDY. BMC PSYCHIATRY, 2, 4. HTTP://DX.DOI.ORG/10.1186/1471-244X-2-4</mixed-citation></ref><ref id="scirp.48094-ref10"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>TREC</surname><given-names> COLLABORATIVE</given-names></name>,<name name-style="western"><surname> GROUP </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2003</year>)<article-title>RAPID TRANQUILLISATION FOR AGITATED PATIENTS IN EMERGENCY PSYCHIATRIC ROOMS: A RANDOMISED TRIAL OF MIDAZOLAM VERSUS HALOPERIDOL PLUS PROMETHAZINE</article-title><source>. BMJ</source><volume> 327</volume>,<fpage> 708</fpage>-<lpage>713</lpage>.<pub-id pub-id-type="doi">HTTP://DX.DOI.ORG/10.1136/BMJ.327.7417.708</pub-id></mixed-citation></ref><ref id="scirp.48094-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">GIBSON, R., FENTON, M., COUTINHO, E. AND CAMPBELL, C. (2005) ZUCLOPENTHIXOL ACETATE IN THE TREATMENT OF ACUTE SCHIZOPHRENIA AND SIMILAR SERIOUS MENTAL ILLNESSES. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, ARTICLE NO: CD000525. HTTP://DX.DOI.ORG/10.1002/14651858.CD000525.PUB2</mixed-citation></ref><ref id="scirp.48094-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">MCGORRY, P. (2004) ROYAL AUSTRALIAN AND NEW ZEALAND COLLEGE OF PSYCHIATRISTS: CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT OF SCHIZOPHRENIA AND RELATED DISORDERS. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 39, 1-30</mixed-citation></ref><ref id="scirp.48094-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">CANADIAN PSYCHIATRIC ASSOCIATION (2005) CLINICAL PRACTICE GUIDELINES: TREATMENT OF SCHIZOPHRENIA. THE CANADIAN JOURNAL OF PSYCHIATRY, 50, 1-56.</mixed-citation></ref></ref-list></back></article>